Cost-Effectiveness of Ibrutinib in Patients With Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL) in England

Value in Health - United Kingdom
doi 10.1016/j.jval.2017.08.246
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Modelling the Effectiveness of Ibrutinib Versus Physician’s Choice (PC) in Relapsed or Refractory (RR) Waldenström’s Macroglobulinemia (WM) Within England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Analysis of Treatment Options for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

A Comparison of the Appraisals by the English National Institute for Health and Care Excellence (NICE) for Two Therapies for Relapsed or Refractory (RR) Chronic Lymphocytic Leukaemia (CLL): Idelalisib+Rituximab (IR) and Ibrutinib

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)

Current Hematologic Malignancy Reports
Cancer ResearchOncologyHematology
2016English

Psy81 - Direct Costs Associated With the Treatment of Chronic Lymphocytic Leukemia (Cll) Relapsed or Refractory in Argentina

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Utility of Idelalisib in Combination With Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Safety and Efficacy of Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Who Have Undergone Prior Allogeneic Stem Cell Transplant

Biology of Blood and Marrow Transplantation
TransplantationHematology
2015English

Transcend CLL 004: Minimal Residual Disease After Lisocabtagene Maraleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy